[go: up one dir, main page]

HUP9900929A2 - Hepatitisz C-ben szenvedő betegek ismételt kezelési eljárásai konszenzus interferonnal - Google Patents

Hepatitisz C-ben szenvedő betegek ismételt kezelési eljárásai konszenzus interferonnal

Info

Publication number
HUP9900929A2
HUP9900929A2 HU9900929A HUP9900929A HUP9900929A2 HU P9900929 A2 HUP9900929 A2 HU P9900929A2 HU 9900929 A HU9900929 A HU 9900929A HU P9900929 A HUP9900929 A HU P9900929A HU P9900929 A2 HUP9900929 A2 HU P9900929A2
Authority
HU
Hungary
Prior art keywords
retreatment
hepatitis
methods
consensus interferon
patients afflicted
Prior art date
Application number
HU9900929A
Other languages
English (en)
Inventor
Larry Blatt
Michael Klein
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of HUP9900929A2 publication Critical patent/HUP9900929A2/hu
Publication of HUP9900929A3 publication Critical patent/HUP9900929A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány tárgya eljárás HCV-fertőzésben szenvedő őlyan betegekismételt kezelésére kőnszenzűs interferőn hatékőny mennyiségével,akiknél a szérűm ALT-szintek a kőrábbi interferőnkezelést követőenmeghaladják a nőrmál érték felső határát. ŕ
HU9900929A 1996-02-05 1997-01-13 Methods for retreatment of patients afflicted with hepatitis c using consensus interferon HUP9900929A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/595,440 US5980884A (en) 1996-02-05 1996-02-05 Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon

Publications (2)

Publication Number Publication Date
HUP9900929A2 true HUP9900929A2 (hu) 1999-07-28
HUP9900929A3 HUP9900929A3 (en) 1999-11-29

Family

ID=24383236

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9900929A HUP9900929A3 (en) 1996-02-05 1997-01-13 Methods for retreatment of patients afflicted with hepatitis c using consensus interferon

Country Status (15)

Country Link
US (1) US5980884A (hu)
EP (1) EP0879059A1 (hu)
JP (1) JP2000504010A (hu)
KR (1) KR19990082084A (hu)
CN (1) CN1217660A (hu)
AU (1) AU1531897A (hu)
BR (1) BR9700829A (hu)
CZ (1) CZ231998A3 (hu)
EA (1) EA199800674A1 (hu)
HU (1) HUP9900929A3 (hu)
IL (1) IL125494A0 (hu)
NO (1) NO983410L (hu)
SK (1) SK101798A3 (hu)
WO (1) WO1997027866A1 (hu)
ZA (1) ZA97721B (hu)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000506839A (ja) * 1996-02-28 2000-06-06 アイエフアイ ノスチチュート ファルマコテラピコ イタリアーノ ソシエタ ペル アチオニ 天然ヒトα―インターフェロンを含む薬剤組成物
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EA200601591A1 (ru) * 2000-05-26 2007-02-27 Айденикс (Кайман) Лимитед Применение рибонуклеозидных соединений для лечения флавивирусных и пестивирусных инфекций
AU2002227252A1 (en) * 2000-12-01 2002-06-11 Cornell Research Foundation Animal model for flaviviridae infection
US20050079579A1 (en) * 2001-02-28 2005-04-14 Guangwen Wei Uses of spatial configuration to modulate protein function
US20060035327A1 (en) * 2001-02-28 2006-02-16 Guangwen Wei Recombinant super-compound interferon and uses thereof
CN1245215C (zh) * 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
US8551469B2 (en) * 2001-02-28 2013-10-08 Superlab Far East Limited Treatment of tumors and viral diseases with recombinant interferon alpha
PL369129A1 (en) * 2001-09-28 2005-04-18 Intermune, Inc. Method for treating hepatitis c virus infection in treatment failure patients
EP1435997A4 (en) * 2001-09-28 2006-03-01 Intermune Inc TECHNIQUE FOR TREATING HEPATITIS C VIRUS INFECTION FOR PATIENTS WHOSE TREATMENT FAILED
WO2003026589A2 (en) * 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
HUP0401818A2 (hu) * 2001-10-05 2004-11-29 Intermune, Inc. Eljárás hepatitis vírusfertőzés kezelésére multifázisos interferon felszabadulású profillal
JP2005508935A (ja) * 2001-10-05 2005-04-07 インターミューン インコーポレイテッド 肝線維症およびｃ型肝炎ウイルス感染症を治療する方法
JP2005517648A (ja) * 2001-12-07 2005-06-16 インターミューン インコーポレイテッド 肝炎ウイルス感染症を治療するための組成物および方法
EP1480982A4 (en) * 2002-02-14 2007-08-01 Pharmasset Inc MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES
US20040063912A1 (en) * 2002-03-15 2004-04-01 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
US20030199464A1 (en) * 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
TW200500373A (en) 2002-06-28 2005-01-01 Idenix Cayman Ltd 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
EP1536804A4 (en) 2002-06-28 2007-10-31 Idenix Cayman Ltd 2'-C-METHYL-3'-O-L-VALINESTER-RIBOFURANOSYLCYTIDINE FOR THE TREATMENT OF FLAVIVIRIDAE INFECTIONS
JP2006519753A (ja) 2002-11-15 2006-08-31 イデニクス（ケイマン）リミテツド ２’−分枝ヌクレオシドおよびフラビウイルス科ウイルス突然変異
US7598373B2 (en) 2002-12-12 2009-10-06 Idenix Pharmaceuticals, Inc. Process for the production of 2-C-methyl-D-ribonolactone
US20070077225A1 (en) * 2003-02-28 2007-04-05 Blatt Lawrence M Continuous delivery methods for treating hepatitis virus infection
AU2003225670A1 (en) * 2003-02-28 2004-09-28 Intermune, Inc. Interferon drug therapy for the treatment of viral diseases and liver fibrosis
EP2345659A1 (en) 2003-05-30 2011-07-20 Pharmasset, Inc. Modified fluorinated nucleoside analogues
US7585647B2 (en) * 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
US20050208019A1 (en) * 2003-08-28 2005-09-22 Guangwen Wei Uses of interferons with altered spatial structure
WO2005037214A2 (en) 2003-10-14 2005-04-28 Intermune, Inc. Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
JP2007519422A (ja) 2004-02-02 2007-07-19 アンブレツクス・インコーポレイテツド 修飾されたヒト四螺旋バンドルポリペプチド及びそれらの使用
CN1980657A (zh) 2004-05-05 2007-06-13 耶鲁大学 新颖的抗病毒赛菊宁黄质类似物
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
SG158136A1 (en) 2004-09-14 2010-01-29 Pharmasset Inc Preparation of 2`-fluoro-2`- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
MY167668A (en) * 2005-03-09 2018-09-21 Superlab Far East Ltd Uses of recombinant super-compound interferons
US20090148407A1 (en) 2005-07-25 2009-06-11 Intermune, Inc. Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication
EA200801050A1 (ru) 2005-10-11 2008-12-30 Интермьюн, Инк. Соединения и способы ингибирования репликации вирусного гепатита с
JP5254033B2 (ja) 2005-12-23 2013-08-07 イデニク プハルマセウティカルス，インコーポレイテッド 分岐型ヌクレオシドを調製するための合成中間体の製造方法
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
BRPI0922508A8 (pt) 2008-12-23 2016-01-19 Pharmasset Inc Análogos de nucleosídeo
KR20110099138A (ko) 2008-12-23 2011-09-06 파마셋 인코포레이티드 뉴클레오시드 포스포르아미데이트
CA2748016A1 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Synthesis of purine nucleosides
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
EP2440251A4 (en) * 2009-06-09 2013-01-16 Defyrus Inc INTERFERON ADMINISTRATION FOR PROPHYLAXIS AGAINST PATHOGEN INFECTION OR TREATMENT OF PATHOGEN INFECTION
EP2459211A1 (en) 2009-07-31 2012-06-06 Medtronic, Inc. Continuous subcutaneous administration of interferon- to hepatitis c infected patients
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
UY33311A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidatos de nucleosidos
CN102711871A (zh) 2010-06-16 2012-10-03 麦德托尼克公司 用于稳定药物递送装置中的药物的阻尼系统
ES2716158T3 (es) 2010-11-30 2019-06-10 Gilead Pharmasset Llc 2'-spiro-nucleótidos para el tratamiento de hepatitis C
DE112012003510T5 (de) 2011-10-21 2015-03-19 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
DK2583680T1 (da) 2011-10-21 2015-01-19 Abbvie Inc Mono (PSI-7977) eller kombinationsbehandling af DAA til anvendelse ved behandling af HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
TW201427681A (zh) 2013-01-07 2014-07-16 Superlab Far East Ltd 用空間構象改變的重組干擾素治療腫瘤的方法
JP2016529293A (ja) 2013-08-27 2016-09-23 ギリアド ファーマセット エルエルシー ２つの抗ウイルス化合物の組合せ製剤
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect

Also Published As

Publication number Publication date
BR9700829A (pt) 1998-07-07
CZ231998A3 (cs) 1999-03-17
IL125494A0 (en) 1999-03-12
US5980884A (en) 1999-11-09
AU1531897A (en) 1997-08-22
CN1217660A (zh) 1999-05-26
KR19990082084A (ko) 1999-11-15
ZA97721B (en) 1997-08-01
EA199800674A1 (ru) 1999-02-25
JP2000504010A (ja) 2000-04-04
EP0879059A1 (en) 1998-11-25
NO983410D0 (no) 1998-07-23
WO1997027866A1 (en) 1997-08-07
NO983410L (no) 1998-10-05
HUP9900929A3 (en) 1999-11-29
SK101798A3 (en) 2000-03-13

Similar Documents

Publication Publication Date Title
HUP9900929A2 (hu) Hepatitisz C-ben szenvedő betegek ismételt kezelési eljárásai konszenzus interferonnal
DK1391215T3 (da) Automatiseret infusionssystem med kalkulator til dosishastighed
DK0831852T3 (da) Nukleosider med anti-hepatitis B-virusaktivitet
FI962613L (fi) Menetelmä inaktivointikäsittelyn virusinaktivointikapasiteetin määrittämiseksi
IT8122814A0 (it) Saggio e vaccino per epatite non-a, non-b.
NO941310D0 (no) Sammensetning og fremgangsmåte for behandling av hepatitt C
TR199900722T2 (xx) Yeniden kurulmu� insan anti-HM1.24 antikoru.
DE3780091D1 (de) Behandlung von pilzinfektionen.
DK447489A (da) Metode til stabilisering af blod
ES2155834T3 (es) Procedimiento de tratamiento de lesiones o de disminuciones celulares.
DE60139466D1 (de) Behandlung von diabetes
DE69022944D1 (de) Verbesserte Methode für anisotropisches Ätzen von Siliziumscheiben und Lösung dafür.
NO871862D0 (no) Fremgangsmaate for paavisning av aids-virusinfeksjon.
DE3782151D1 (de) Verfahren zur fabrikation von alkylhalosilanen und silizium dafuer.
DE69627672D1 (de) Methode zur Feststellung der Auswirkungen von Plasmabehandlungen auf Halbleiterscheiben
DE3885913D1 (de) Aufbereitung von Alkoxysilanen.
PH31116A (en) Methods for the treatment of infection caused by hepatitis B virus (hbv).
DE3784684D1 (de) Fehlerkorrekturdecoder fuer schnelle behandlung von pufferueberlaeufen.
ATE220332T1 (de) Behandlung von hepatitis b mit thymosin alpha 1 und lamivudin
DE68903208D1 (de) Verfahren zur thermischen behandlung von laktoferrin.
DE69428112D1 (de) Verwendung von thymosin zur behandlung von hepatitis c bei patienten, die auf interferongaben nicht ansprechen
DE58902675D1 (de) Verfahren zur steigerung des anteils an siliciumtetrachlorid.
ZA902912B (en) Method of inhibiting induction of latent or chronic viral infection
WO1998006431A3 (en) Method for treating diabetes
DK0900085T3 (da) Behandling af overdreven aggression med olanzapin